Lung Cancer Mutation Consortium Protocol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01014286|
Recruitment Status : Active, not recruiting
First Posted : November 16, 2009
Last Update Posted : February 1, 2019
|Condition or disease|
|Adenocarcinoma of Lung, Stage IV|
|Study Type :||Observational|
|Actual Enrollment :||1100 participants|
|Official Title:||Lung Cancer Mutation Consortium Protocol|
|Study Start Date :||September 2009|
|Estimated Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||July 2019|
Stage IV adenocarcinoma who have undergone biopsy with remnant tissue.
- Frequency of oncogenic mutations in patients with advanced adenocarcinoma of the lung. [ Time Frame: Five years ]The primary objective of this protocol is to determine the frequency of oncogenic mutations in patients with advanced adenocarcinoma of the lung.
- Rate of oncogenic mutations in patients with advanced adenocarcinoma of the lung. [ Time Frame: Five years ]The primary endpoint of this protocol is the mutation rate.
- Associations between each mutation and clinical outcomes. [ Time Frame: Two years ]The secondary objectives of this protocol are to study the associations between each mutation and clinical outcomes, e.g., survival, clinical features, e.g. smoking status, age, and other mutation.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01014286
|United States, Colorado|
|University of Colorado Denver Cancer Center|
|Aurora, Colorado, United States, 80045|
|Study Director:||Paul Bunn, M.D.||University of Colorado, Denver|